10-K: Vitro Biopharma Reports Increased Losses, Eyes Clinical Trials

Vitro Biopharma, an innovative biotechnology company, reported increased net losses for fiscal year 2025, driven by debt extinguishment, while advancing its cell therapy pipeline for autoimmune and inflammatory disorders.

Summary

• Vitro Biopharma reported a net loss of $10.9 million for fiscal year 2025, an increase of 10% from $9.9 million in fiscal year 2024.
• Total revenue increased by 11% to $2.06 million in fiscal year 2025, up from $1.86 million in fiscal year 2024, primarily due to increased sales of AlloRx Stem Cells to foreign clinics.
• The company has a working capital deficit of $4.8 million and an accumulated deficit of $48.8 million as of October 31, 2025, raising substantial doubt about its ability to continue as a going concern.
• Research and development expenses decreased by 14% to $533,028 in fiscal year 2025, with approximately $66,000 allocated to the upcoming Pitt Hopkins trial and $451,000 to ongoing topical dermatological trials for AlloEx.
• The company plans to initiate Phase 1/2a clinical trials in 2026 for Pitt-Hopkins Syndrome (PTHS) and Long COVID, pending IRB approval and sufficient working capital.
• Sales of Fitore products ceased as of March 1, 2025, contributing to an 80% decrease in Fitore revenue in fiscal year 2025.
• The company issued $6.55 million in Senior Secured Convertible Notes and $700,000 in Series A-1 Preferred Stock during fiscal year 2025 to fund operations.
• Preliminary tolerability data from over 617 subjects treated with AlloRx Stem Cells in compassionate use and foreign clinical studies reported no serious adverse events related to the product.
• The company identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties, insufficient written policies, and a limited number of personnel with appropriate accounting knowledge.
• Dr. Caroline Mosessian was not re-elected to the Board of Directors on November 17, 2025, and her consulting agreement was terminated effective December 31, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to significant financial losses, a going concern warning, and identified material weaknesses in internal controls, despite some progress in clinical development and revenue growth in specific segments.

Positives

• Total revenue increased by 11% to $2.06 million in fiscal year 2025, driven by increased sales of AlloRx Stem Cells to foreign third-party clinics.
• Sales of AlloRx Stem Cells to foreign third-party clinics increased by 13% to $1.45 million in fiscal year 2025, with expectations for continued growth.
• InfiniVive MD revenue increased by 21% to $155,868 in fiscal year 2025, with further increases expected in fiscal year 2026 based on anticipated positive clinical trial data.
• Preliminary tolerability data from over 617 subjects treated with AlloRx Stem Cells in various indications reported no serious adverse events related to the product, suggesting a favorable safety profile.
• The company has FDA authorization for two Phase 1/2a clinical trials for PTHS and Long COVID, with plans to commence in 2026.
• Pre-clinical studies indicate AlloRx Stem Cells (UC-derived MSCs) have advantages over other MSC sources, including faster growth rate, greater immunomodulatory potency, increased cellular ATP expression, and superior cell migration.
• The company's manufacturing facility is cGMP compliant and ISO 9001:2015 and ISO 13485:2016 certified, with capacity to produce over 300 AlloRx Stem Cell therapy treatments per month.
• The company is pursuing non-dilutive funding and grant awards to support clinical research and product development, aiming to reduce reliance on external financing.
• The maturity date for unsecured 6% and 4% notes payable to a related party (Chief Science Officer) was extended from December 31, 2025, to December 31, 2030, providing financial flexibility.

Negatives

• The company incurred a net loss of $10.9 million in fiscal year 2025, an increase of 10% from the $9.9 million loss in fiscal year 2024.
• A working capital deficit of $4.8 million and an accumulated deficit of $48.8 million as of October 31, 2025, raise substantial doubt about the company's ability to continue as a going concern.
• The company recorded a significant loss on extinguishment of debt of $3.69 million in fiscal year 2025.
• Sales of Fitore products ceased as of March 1, 2025, leading to an 80% decrease in Fitore revenue in fiscal year 2025, and the subsidiary is not profitable on a stand-alone basis.
• A significant portion of revenue is concentrated on a few large customers, with three domestic customers accounting for 37%, 20%, and 15% of sales in fiscal year 2025.
• The company has no U.S. patents and only one registered patent in the Bahamas, relying heavily on trade secrets which are difficult to protect and enforce.
• The company has identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties, insufficient written policies, and a lack of personnel with appropriate US GAAP knowledge.
• The company's securities are not listed on any exchange or over-the-counter market, and there is no established public trading market for its common stock.
• The Board of Directors does not currently maintain an audit committee or have an audit committee financial expert, which is a governance weakness.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses, limited revenue, and limited working capital.
• The company is heavily dependent on the successful development and commercialization of AlloRx Stem Cell therapy, and delays or difficulties could harm the business.
• The potential of product candidates, particularly AlloRx Stem Cell therapy, to treat various diseases may not be realized, reducing the value of technology and development programs.
• The company has never commercialized a biologic or drug product candidate and may lack the necessary expertise, personnel, and resources for successful commercialization.
• Product development programs are based on novel technologies and are inherently risky, with no FDA-approved allogeneic, cell-based therapies for targeted indications like PTHS, Long COVID, Lupus (SLE), MS, or Alzheimer's disease.
• Failure to recruit and retain qualified management and scientific personnel could impede financing, collaborations, or technology development.
• Reliance on third-party healthcare professionals to administer AlloRx Stem Cell therapy and AlloRx Stem Cells poses risks if administered incorrectly or if instructions are not followed.
• The company may be unable to develop a new cGMP manufacturing facility on a timely basis or at all, potentially requiring outsourcing and increasing dependence on third parties.
• Interim, topline, and preliminary data from clinical trials may change as more data become available and are subject to audit and verification procedures.
• Competitors may develop similar or comparable treatments more quickly, market them more successfully, or demonstrate greater safety/efficacy, reducing or eliminating commercial opportunity.
• Product candidates derived from human umbilical cords have the potential for disease transmission and are susceptible to ethical concerns surrounding stem cell therapy or human tissue.
• If intellectual property does not adequately protect products and uses, others could compete more directly, harming the business.
• Third-party claims of patent infringement may prevent or delay product development efforts.
• The FDA and other regulatory agencies actively enforce laws and regulations prohibiting the promotion of off-label uses, which could lead to significant liability.
• The FDA and other comparable foreign regulatory authorities may not accept data from trials or studies conducted in locations outside of their jurisdiction, requiring additional costly and time-consuming studies.
• The company's principal stockholders and management own a significant percentage of stock, allowing them to exert significant control over matters subject to stockholder approval.
• Material weaknesses in internal control over financial reporting could lead to inaccurate financial reporting or fraud.
• The coronavirus pandemic caused interruptions or delays in the business plan, and future healthcare emergencies could have similar adverse effects.
• Internal computer systems, or those of third parties, may fail or suffer security/data privacy breaches, leading to costs, loss of revenue, and reputational harm.
• Business activities may be subject to the U.S. Foreign Corrupt Practices Act and similar anti-bribery laws, as well as export controls and trade sanctions, limiting foreign market competition and exposing the company to liability.

Future Outlook

The company expects to continue reporting losses until it can improve operations and/or commercialize product candidates to generate sufficient sales. It anticipates increased AlloRx Stem Cell sales internationally and expects InfiniVive MD revenues to increase in fiscal year 2026 based on expected positive clinical trial data. The company plans to initiate Phase 1/2a clinical trials for PTHS and Long COVID in 2026 and submit additional IND applications for Lupus (SLE) and MS in 2027. It also aims to develop a new cGMP biomanufacturing facility, estimated to cost $1.0 to $3.0 million, to expand manufacturing capabilities and achieve economies of scale.

Management Comments

• Management plans to address the going concern by raising additional capital through public and/or private offerings of equity securities, potentially issuing additional debt and equity instruments.
• Management has various initiatives underway to increase revenue generation through diversified offerings of products and services related to its stem cell technology and analytical capabilities, with the goal of achieving profitable operations as quickly as possible.
• Management believes that the fair value assigned to the intangible assets acquired is based on reasonable assumptions and estimates that a market participant would use.

Industry Context

StockSavvy.ai notes that Vitro Biopharma operates in the highly competitive and rapidly advancing biotechnology and regenerative medicine sector, characterized by significant R&D costs and regulatory hurdles. The company's focus on allogeneic cell therapies for autoimmune and inflammatory disorders, including rare neurogenetic conditions like PTHS and emerging conditions like Long COVID, positions it in areas of high unmet medical need but also high risk due to the novel nature of the treatments. The lack of FDA-approved allogeneic cell therapies for its target indications highlights the pioneering, yet challenging, regulatory pathway. The company's strategy to leverage preliminary data from foreign clinical studies to support U.S. INDs is a common approach to de-risk early-stage development and conserve resources, but FDA acceptance of such data is not guaranteed. The cessation of Fitore product sales reflects the challenges of diversifying into non-core, competitive markets like dietary supplements.

Comparison to Industry Standards

• Vitro Biopharma's AlloRx Stem Cells (UC-derived MSCs) demonstrated superior growth rate (doubling in 25 hours) compared to AD-MSCs (56.4 hours), P-MSCs (40 hours), and BM-MSCs (53 hours) in pre-clinical in vitro studies, suggesting a potential manufacturing advantage over competitors using other MSC sources.
• AlloRx Stem Cells showed approximately two-fold greater maximal IDO activity at 10 ng/ml -IFN compared to AD-MSCs, BM-MSCs, and P-MSCs, indicating potentially higher immunomodulatory potency, which is a key therapeutic mechanism for inflammatory and autoimmune disorders.
• In terms of cellular ATP expression, AlloRx Stem Cells showed a significant difference, suggesting increased mitochondrial functionality compared to AD-MSCs, P-MSCs, and BM-MSCs, which could imply greater cellular energy and therapeutic activity.
• AlloRx Stem Cells exhibited superior cell migration in response to Substance P (~40% closure in 72 hours) compared to AD-MSC, P-MSC, and BM-MSC (5-15% closure), potentially indicating a faster ability to migrate to injury sites in the body.
• The company's manufacturing facility is cGMP compliant and ISO 9001:2015 and ISO 13485:2016 certified, aligning with high industry quality standards for biopharmaceutical production.
• Unlike many early-stage biotechnology competitors that do not generate revenue, Vitro Biopharma generates revenue from MSC-Gro sales, AlloRx Stem Cell supply to foreign clinics, and InfiniVive MD cosmetic products, providing some internal funding for R&D.
• The company faces competition from well-capitalized cellular therapy companies like Athersys, BrainStorm Cell Therapeutics, Celularity, Healios, Longeveron, and Mesoblast, many of which have greater financial, scientific, and marketing resources and more advanced clinical pipelines for various indications.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings, government actions, administrative actions, investigations, or claims are currently pending against the company or its officers and directors in which the company is adverse.

Related Party Transactions

• The company has outstanding promissory notes to its Chief Science Officer and Director, Dr. James Musick, totaling approximately $2.0 million in aggregate principal amount as of October 31, 2025, with accrued interest of $474,838. The maturity date for these notes was extended to December 31, 2030.
• Dr. Jack Zamora, former Chief Executive Officer and former director, beneficially owned approximately 31% of the company's voting stock as of January 29, 2024, and granted an irrevocable proxy to Christopher Furman.
• The company entered into a Supply Agreement with Dr. Zamora on November 20, 2022, to provide InfiniVive MD Exosome Serum and Daily Serum, with Dr. Zamora purchasing approximately $105,750 of Cosmetic Products as of January 26, 2026.
• A Memorandum of Understanding (MOU) was entered into with Dr. Zamora on November 20, 2022, to provide AlloRx Stem Cells to international clinical research facilities he may be affiliated with, for a period of five years.
• Dr. Zamora accounted for $36,000 in product sales in fiscal year 2025 and $33,750 in fiscal year 2024, representing 2% of total sales in both years.
• The spouse of the Chief Science Officer, through controlled entities, leases office and lab space to the company at $5,645 per month, with the lease running through June 2030.

Stakeholder Impact

• **Shareholders:** Face substantial doubt about the company's ability to continue as a going concern, increased net losses, and potential dilution from future capital raises. The lack of a public trading market limits liquidity and valuation transparency.
• **Employees:** The company plans to grow its organization and hire additional managerial, operational, sales, marketing, and financial personnel, which could create new opportunities. However, the company's financial instability poses a risk to job security.
• **Customers (Foreign Clinics/Medical Centers):** Benefit from continued supply of AlloRx Stem Cells and MSC-Gro, with increasing sales volumes. However, the lack of formal written agreements for many supply arrangements introduces uncertainty.
• **Customers (InfiniVive MD):** May see continued product development and marketing efforts, with expected revenue growth. However, potential regulatory scrutiny on cosmetic claims and competition remain risks.
• **Creditors:** The company has significant outstanding debt, including to related parties, and its ability to make scheduled payments depends on future performance and additional capital. Debt extensions provide some relief but highlight underlying financial challenges.
• **Patients (Clinical Trials):** Potential beneficiaries of AlloRx Stem Cell therapy for serious conditions like PTHS and Long COVID, with clinical trials planned. However, delays in trials or failure to achieve efficacy could impact patient access to potential treatments.
• **Regulatory Bodies (FDA):** The company is actively engaging with the FDA for INDs and ODD, indicating compliance efforts. However, the evolving regulatory landscape for novel cell therapies and the need for robust clinical data present ongoing challenges.

Next Steps

• Initiate Phase 1/2a clinical trials for Pitt-Hopkins Syndrome (PTHS) and Long COVID in 2026, pending IRB approval and clinical trial agreements.
• Submit an amendment to the Orphan Drug Designation (ODD) request for PTHS once initial clinical data from the Phase 1/2a trial becomes available.
• Submit two additional IND applications to FDA in 2027 to initiate Phase 1/2a clinical trials for Lupus (SLE) and Multiple Sclerosis (MS).
• Advance preclinical research and development activities for AlloRx Stem Cell therapy for Alzheimer's disease with the goal of a future IND filing.
• Investigate AlloRx Stem Cells in an animal model of ALS to test various cohorts and seek grant funding for these studies.
• Continue to supply AlloRx Stem Cells to foreign third-party clinics and medical centers for use in foreign clinical studies to gain additional human experience.
• Develop a new cGMP biomanufacturing facility using highly scalable, fully automated closed system bioprocessing, once necessary capital resources are obtained.
• Continue to generate value by commercializing existing products and technologies (MSC-Gro, CAFs, InfiniVive MD products) to support internal development efforts.
• Pursue additional collaboration arrangements and out-licensing opportunities for product candidates.
• Seek non-dilutive funding and grant awards to support clinical research and product candidate development.
• Address and remediate identified material weaknesses in internal control over financial reporting.
• Appoint additional independent directors and create an audit committee with an audit committee financial expert in connection with anticipated future public offering and listing on a national securities exchange.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a 'substantial doubt about its ability to continue as a going concern' warning from its auditors, a significant accumulated deficit of $48.8 million, and a working capital deficit of $4.8 million. While revenue saw a modest increase, net losses widened, and the company relies heavily on future capital raises, which will likely dilute existing shareholders. The identified material weaknesses in internal controls and the absence of an audit committee further compound governance risks. Despite promising preclinical data and planned clinical trials, the early stage of development, intense competition, and lack of FDA-approved allogeneic therapies for its target indications mean a long, uncertain, and capital-intensive path to commercialization. The cessation of Fitore product sales indicates challenges in business diversification. Given the high financial risk, significant operational uncertainties, and lack of a public trading market, the stock represents a strong sell for any investor.

Keywords

Biotechnology, Regenerative Medicine, Cell Therapy, AlloRx Stem Cells, Autoimmune Disorders, Inflammatory Disorders, Pitt-Hopkins Syndrome, Long COVID, Lupus (SLE), Multiple Sclerosis (MS), Alzheimer's Disease, Clinical Trials, FDA Approval, Orphan Drug Designation, cGMP Manufacturing, MSC-Gro, InfiniVive MD, SEC Filing, Going Concern, Convertible Notes